FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2521555087> ?p ?o ?g. }

• W2521555087 endingPage "163" @default.
• W2521555087 startingPage "157" @default.
• W2521555087 abstract "Background & AimsThere is controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrhosis and refractory ascites. The high rate of shunt dysfunction with the use of uncovered stents counteracts the benefits of TIPS. We performed a randomized controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in these patients.MethodsWe performed a prospective study of 62 patients with cirrhosis and at least 2 large-volume paracenteses within a period of at least 3 weeks; the study was performed at 4 tertiary care centers in France from August 2005 through December 2012. Patients were randomly assigned to groups that received covered TIPS (n = 29) or large-volume paracenteses and albumin as necessary (LVP+A, n = 33). All patients maintained a low-salt diet and were examined at 1 month after the procedure then every 3 months until 1 year. At each visit, liver disease–related complications, treatment modifications, and clinical and biochemical variables needed to calculate Child-Pugh and Model for End-Stage Liver Disease scores were recorded. Doppler ultrasonography was performed at the start of the study and then at 6 and 12 months after the procedure. The primary study end point was survival without a liver transplant for 1 year after the procedure.ResultsA higher proportion of patients in the TIPS group (93%) met the primary end point than in the LVP+A group (52%) (P = .003). The total number of paracenteses was 32 in the TIPS group vs 320 in the LVP+A group. Higher proportions of patients in the LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01) or hernia-related complications (18% vs 0%; P = .01) than in the TIPS group. Patients in LVP+A group had twice as many days of hospitalization (35 days) as the TIPS group (17 days) (P = .04). The 1-year probability of remaining free of encephalopathy was 65% for each group.ConclusionsIn a randomized trial, we found covered stents for TIPS to increase the proportion of patients with cirrhosis and recurrent ascites who survive transplantation-free for 1 year, compared with patients given repeated LVP+A. These findings support TIPS as the first-line intervention in such patients. ClinicalTrials.gov ID: NCT00222014. There is controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrhosis and refractory ascites. The high rate of shunt dysfunction with the use of uncovered stents counteracts the benefits of TIPS. We performed a randomized controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in these patients. We performed a prospective study of 62 patients with cirrhosis and at least 2 large-volume paracenteses within a period of at least 3 weeks; the study was performed at 4 tertiary care centers in France from August 2005 through December 2012. Patients were randomly assigned to groups that received covered TIPS (n = 29) or large-volume paracenteses and albumin as necessary (LVP+A, n = 33). All patients maintained a low-salt diet and were examined at 1 month after the procedure then every 3 months until 1 year. At each visit, liver disease–related complications, treatment modifications, and clinical and biochemical variables needed to calculate Child-Pugh and Model for End-Stage Liver Disease scores were recorded. Doppler ultrasonography was performed at the start of the study and then at 6 and 12 months after the procedure. The primary study end point was survival without a liver transplant for 1 year after the procedure. A higher proportion of patients in the TIPS group (93%) met the primary end point than in the LVP+A group (52%) (P = .003). The total number of paracenteses was 32 in the TIPS group vs 320 in the LVP+A group. Higher proportions of patients in the LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01) or hernia-related complications (18% vs 0%; P = .01) than in the TIPS group. Patients in LVP+A group had twice as many days of hospitalization (35 days) as the TIPS group (17 days) (P = .04). The 1-year probability of remaining free of encephalopathy was 65% for each group. In a randomized trial, we found covered stents for TIPS to increase the proportion of patients with cirrhosis and recurrent ascites who survive transplantation-free for 1 year, compared with patients given repeated LVP+A. These findings support TIPS as the first-line intervention in such patients. ClinicalTrials.gov ID: NCT00222014." @default.
• W2521555087 created "2016-09-30" @default.
• W2521555087 creator A5003944446 @default.
• W2521555087 creator A5004361418 @default.
• W2521555087 creator A5029253450 @default.
• W2521555087 creator A5040277254 @default.
• W2521555087 creator A5062077592 @default.
• W2521555087 creator A5067483186 @default.
• W2521555087 creator A5069285807 @default.
• W2521555087 creator A5071323583 @default.
• W2521555087 creator A5073789519 @default.
• W2521555087 creator A5075393352 @default.
• W2521555087 creator A5084045169 @default.
• W2521555087 date "2017-01-01" @default.
• W2521555087 modified "2023-10-17" @default.
• W2521555087 title "Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites" @default.
• W2521555087 cites W1228830179 @default.
• W2521555087 cites W1971058407 @default.
• W2521555087 cites W1975539433 @default.
• W2521555087 cites W1989240619 @default.
• W2521555087 cites W1996571028 @default.
• W2521555087 cites W2001137775 @default.
• W2521555087 cites W2015839847 @default.
• W2521555087 cites W2025027100 @default.
• W2521555087 cites W2036408424 @default.
• W2521555087 cites W2036774791 @default.
• W2521555087 cites W2038420606 @default.
• W2521555087 cites W2048876151 @default.
• W2521555087 cites W2075662049 @default.
• W2521555087 cites W2090637752 @default.
• W2521555087 cites W2094731187 @default.
• W2521555087 cites W2098005391 @default.
• W2521555087 cites W2108321458 @default.
• W2521555087 cites W2111820868 @default.
• W2521555087 cites W2134599653 @default.
• W2521555087 cites W2142639596 @default.
• W2521555087 cites W2148680569 @default.
• W2521555087 cites W2161363401 @default.
• W2521555087 cites W2170974768 @default.
• W2521555087 cites W2318484454 @default.
• W2521555087 cites W3144171032 @default.
• W2521555087 cites W4362208328 @default.
• W2521555087 doi "https://doi.org/10.1053/j.gastro.2016.09.016" @default.
• W2521555087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27663604" @default.
• W2521555087 hasPublicationYear "2017" @default.
• W2521555087 type Work @default.
• W2521555087 sameAs 2521555087 @default.
• W2521555087 citedByCount "280" @default.
• W2521555087 countsByYear W25215550872017 @default.
• W2521555087 countsByYear W25215550872018 @default.
• W2521555087 countsByYear W25215550872019 @default.
• W2521555087 countsByYear W25215550872020 @default.
• W2521555087 countsByYear W25215550872021 @default.
• W2521555087 countsByYear W25215550872022 @default.
• W2521555087 countsByYear W25215550872023 @default.
• W2521555087 crossrefType "journal-article" @default.
• W2521555087 hasAuthorship W2521555087A5003944446 @default.
• W2521555087 hasAuthorship W2521555087A5004361418 @default.
• W2521555087 hasAuthorship W2521555087A5029253450 @default.
• W2521555087 hasAuthorship W2521555087A5040277254 @default.
• W2521555087 hasAuthorship W2521555087A5062077592 @default.
• W2521555087 hasAuthorship W2521555087A5067483186 @default.
• W2521555087 hasAuthorship W2521555087A5069285807 @default.
• W2521555087 hasAuthorship W2521555087A5071323583 @default.
• W2521555087 hasAuthorship W2521555087A5073789519 @default.
• W2521555087 hasAuthorship W2521555087A5075393352 @default.
• W2521555087 hasAuthorship W2521555087A5084045169 @default.
• W2521555087 hasBestOaLocation W25215550871 @default.
• W2521555087 hasConcept C126322002 @default.
• W2521555087 hasConcept C141071460 @default.
• W2521555087 hasConcept C168563851 @default.
• W2521555087 hasConcept C203092338 @default.
• W2521555087 hasConcept C2776283816 @default.
• W2521555087 hasConcept C2777075537 @default.
• W2521555087 hasConcept C2777214474 @default.
• W2521555087 hasConcept C2778808290 @default.
• W2521555087 hasConcept C2779250428 @default.
• W2521555087 hasConcept C2779609443 @default.
• W2521555087 hasConcept C2780496750 @default.
• W2521555087 hasConcept C2781033279 @default.
• W2521555087 hasConcept C2911091166 @default.
• W2521555087 hasConcept C71924100 @default.
• W2521555087 hasConcept C90924648 @default.
• W2521555087 hasConceptScore W2521555087C126322002 @default.
• W2521555087 hasConceptScore W2521555087C141071460 @default.
• W2521555087 hasConceptScore W2521555087C168563851 @default.
• W2521555087 hasConceptScore W2521555087C203092338 @default.
• W2521555087 hasConceptScore W2521555087C2776283816 @default.
• W2521555087 hasConceptScore W2521555087C2777075537 @default.
• W2521555087 hasConceptScore W2521555087C2777214474 @default.
• W2521555087 hasConceptScore W2521555087C2778808290 @default.
• W2521555087 hasConceptScore W2521555087C2779250428 @default.
• W2521555087 hasConceptScore W2521555087C2779609443 @default.
• W2521555087 hasConceptScore W2521555087C2780496750 @default.
• W2521555087 hasConceptScore W2521555087C2781033279 @default.
• W2521555087 hasConceptScore W2521555087C2911091166 @default.
• W2521555087 hasConceptScore W2521555087C71924100 @default.
• W2521555087 hasConceptScore W2521555087C90924648 @default.

• next